Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Selected as a solid growth name with raised 2025 guidance supported by strong diagnostic product adoption and margin expansion; upcoming Nov 3 Q3 earnings represent key catalyst amid moderate technical weakness requiring caution.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Margins ⢠Robust Cash Flow ⢠Rising Leverage IDXX delivers exceptional profitability and cash flow, but elevated valuation, rising debt, and weakening liquidity warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Below average ⢠Support test Support Level: $500.00 Resistance Level: $520.00â$535.00; stronger at $545.00â$557.00 IDXX remains bearish over the last month, trading below its moving average near $542.73, though support around $500 and RSI near 34 could enable a rebound if it clears $520â$535 resistance.
Sentiment & News
Key News Insights: ⢠Raised EPS outlook ⢠Premium valuation ⢠Mixed institutional flows IDEXX's strong recurring-growth outlook and raised 2026 EPS guidance support long-term upside, but premium valuation, weaker U.S. vet traffic and mixed investor activity warrant patience.
AI Summary
IDEXX's selloff presents an opportunity only if recurring diagnostics, pricing, and productivity continue offsetting softer U.S. veterinary traffic, as its ~41x earnings valuation leaves little tolerance for growth or margin disappointment.
Description
IDEXX Laboratories develops, manufactures, and sells diagnostic instruments, consumables, laboratory services, and practice management software for veterinary, livestock, dairy and water-testing markets worldwide. Its offerings include point-of-care and reference laboratory diagnostics, imaging and monitoring systems, and microbiological water tests, supported by sales, technical service teams and distribution partners. The company also supplies certain human point-of-care analyzers; it was founded in 1983 and is headquartered in Westbrook, Maine.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 3 | Nov 10 | IDXX | IDEXX Laboratories, Inc. | Selected as a solid growth name with raised 2025 guidance supported by strong diagnostic product adoption and margin expansion; upcoming Nov 3 Q3 earnings represent key catalyst amid moderate technical weakness requiring caution. | Closed | -1.8% |